LogicBio Therapeutics Inc
Change company Symbol lookup
Select an option...
LOGC LogicBio Therapeutics Inc
OSUR OraSure Technologies Inc
KMI Kinder Morgan Inc
RSG Republic Services Inc
TGEN Tecogen Inc
EPAM Epam Systems Inc
ISLE Isleworth Healthcare Acquisition Corp
TRMD Torm PLC
THC Tenet Healthcare Corp
BKCC BlackRock Capital Investment Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Blend
Company profile

LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1. It is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Price
Delayed
$0.395
Day's Change
-0.0015 (-0.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.4599
Day's Low
0.391
Volume
(Light)

Today's volume of 30,837 shares is on pace to be much lighter than LOGC's 10-day average volume of 200,440 shares.

30,837

Display:

Providers:

UpdateCancel
6 providers
May 17, 2022
LogicBio(R) Therapeutics to Present at H.C. Wainwright Global Investment Conference

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference...(PR Newswire)

May 16, 2022
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LogicBio to present at ASGCT 2022 Annual Meeting (PR Newswire)

May 11, 2022
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

GeneRide(R) LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers Proprietary AAV transfection process, harnessing mAAVRx(TM) system, showed 15- to 30-fold yield increase over standard processes (PR Newswire)

May 09, 2022
Thinking about buying stock in LogicBio Therapeutics, Rivian Automotive, Lucid Group, Party City, or Nikola Corp?

InvestorsObserver issues critical PriceWatch Alerts for LOGC, RIVN, LCID, PRTY, and NKLA. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

Company initiates activities to resume dosing Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LogicBio(R) Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.